<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> type 1 (AT(1)) receptor blockers (ARBs) are known to prevent the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo> and to attenuate neural damage </plain></SENT>
<SENT sid="1" pm="."><plain>Additional beneficial effects of ARBs, independent of AT(1) receptor blockade, have been highlighted </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="5959">Irbesartan</z:chebi> is reported to act as an <z:chebi fb="68" ids="48706">antagonist</z:chebi> of the monocyte chemoattractant protein-1 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1) receptor, C-C chemokine receptor 2 (CCR2), due to its molecular structure </plain></SENT>
<SENT sid="3" pm="."><plain>We examined the possible synergistic effects of co-administration of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> with <z:chebi fb="0" ids="32060">propagermanium</z:chebi>, a CCR2 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, on ischemic brain damage </plain></SENT>
<SENT sid="4" pm="."><plain>Administration of <z:chebi fb="0" ids="32060">propagermanium</z:chebi> decreased ischemic brain area after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>To study the possible synergistic effects of <z:chebi fb="0" ids="32060">propagermanium</z:chebi> with ARBs, we employed non-effective lower doses of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> and <z:chebi fb="0" ids="6541">losartan</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> with <z:chebi fb="0" ids="32060">propagermanium</z:chebi> decreased the ischemic brain area more markedly compared with <z:chebi fb="0" ids="32060">propagermanium</z:chebi> alone, but co-administration of <z:chebi fb="0" ids="6541">losartan</z:chebi> did not </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="17" ids="50099">MCP</z:chebi>-1 mRNA level was significantly increased on the ipsilateral side after MCAO, and administration of <z:chebi fb="0" ids="5959">irbesartan</z:chebi> with <z:chebi fb="0" ids="32060">propagermanium</z:chebi> decreased the <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 level, whereas co-administration of <z:chebi fb="0" ids="6541">losartan</z:chebi> did not </plain></SENT>
<SENT sid="8" pm="."><plain>Similar results were obtained for <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 protein level </plain></SENT>
<SENT sid="9" pm="."><plain>CCR2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was significantly elevated on the ipsilateral side; however, no significant difference was observed between each group </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of other inflammatory cytokines such as TNF-α and IL-1β also significantly increased on the ipsilateral side, but the expression levels were not changed by each drug treatment </plain></SENT>
<SENT sid="11" pm="."><plain>Taking these findings together, <z:chebi fb="0" ids="5959">irbesartan</z:chebi> exerts more beneficial effects on ischemic brain damage with an <z:chebi fb="17" ids="50099">MCP</z:chebi>-1 receptor blocker, at least due to its inhibitory effects on <z:chebi fb="17" ids="50099">MCP</z:chebi>-1/CCR2 signaling beyond AT(1) receptor blockade </plain></SENT>
</text></document>